Navigation Links
Pfizer joins open-access medicinal chemistry public-private collaboration
Date:6/10/2010

The Structural Genomics Consortium (SGC) and Pfizer today announced that Pfizer will join the SGC-led public-private collaboration to generate small molecule inhibitors "chemical probes" for proteins involved in epigenetic signalling.

Pfizer and GlaxoSmithKline (GSK) are now members of this collaboration, launched in late 2008 with the aim to provide the community with high quality research reagents, free from restriction on use.

Globally the collaboration includes the three SGC laboratories in Oxford, Toronto and Stockholm, the National Institutes of Health Chemical Genomics Center in Bethesda, the Departments of Chemistry and Biochemistry at the University of Oxford, the Department of Chemistry at Ume University and a number of additional collaborators in academia. The program has been awarded a total of US $15M in grant support from the Wellcome Trust, the Ontario Ministry of Research and Innovation in Canada and the Swedish Foundation for Strategic Research to support activities in the UK, Canada and Sweden, respectively.

The collaboration aims to develop small molecules that can stimulate or block the activity of proteins involved in epigenetic control. The study of epigenetics addresses heritable changes in gene function that occur without a change in the DNA sequence. Alterations in these processes are linked to many common diseases, and there is a strong belief that a better understanding of epigenetics could eventually lead to treatments for diseases such as cancer, diabetes, obesity and many psychiatric diseases. Epigenetics is an area of biology that is poorly understood and the availability of chemical probes should dramatically increase our understanding; some of these probes may also be starting points for drug discovery.

Pfizer is joining the program after having formalized an agreement with the University of Oxford, SGC and GSK. Pfizer will, like GSK, provide medicinal chemistry support to the project. The collaboration is special in that it brings the medicinal chemistry expertise within industry together with the biological expertise within academia to address an emerging area of biology. The ability to add extra industrial members further demonstrates this consortium as a potential working model for pre-competitive interactions between academia and industry within the field of medicinal chemistry.

In keeping with SGC policy, the structure and function of each probe will be made freely available.

Dr Tony Wood, Vice President and Heads of Worldwide Medicinal Chemistry at Pfizer, said: "This collaboration exemplifies our thinking with respect to public-private collaboration that facilitate 'blue sky' research between industry and academia. It is hoped that combining forces in this way will lead to the rapid development and deployment of research tools. This should help us understand the role that this important group of gene families play in human disease and should aid the overarching goal of providing effective medicines to patients."

Dr Aled Edwards, the SGC Chief Executive, adds: "The problem we are tackling together is too big for any single laboratory or organization. We are thrilled that to have two leaders in pharmaceutical research and medicinal chemistry in this global project, and are delighted at this opportunity to collaborate with some of the top medicinal chemists in the world."


'/>"/>

Contact: Johan Weigelt
johan.weigelt@ki.se
46-702-630-255
Wellcome Trust
Source:Eurekalert

Related medicine news :

1. AUDIO from Medialink and Pfizer: Glaucoma - The Sneak Thief of Sight
2. Sigma-Aldrich Reaches Agreement to Sell Pfizers Bioactive Small Molecule Compounds
3. VIDEO from Medialink and National Fibromyalgia Association and Pfizer Inc.: The Science Behind Fibromyalgia
4. Luckey & Mullins Joins with Other National Construction Defect Law Firms to Form Chinese Drywall Legal Network
5. The Chicago Office of McDonald Hopkins Continues to Expand: Healthcare Attorney, Charles F. MacKelvie, Joins the Firms National Healthcare and Healthcare Restructuring Practice Groups
6. Mary Kay Thalken Joins StatCom as Enterprise VP, Western Region
7. CallSource joins Starkey Hearing Foundation to Tackle Children's Hearing Loss in Super Bowl Mission
8. Robert Naticchia Joins CONNEXION Healthcare as Executive Vice President, Client Services
9. Industry Advisor Joins OrthoAccel Technologies, Inc.
10. Worlds #1 Health Brand for Kids Joins Forces With Worlds #1 In-School Childrens Theatre
11. Oncology Industry Veteran, Joe Baffone, Joins onPoint Oncology, LLC.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... Silicon Valley ... even on the go. Their electric toothbrushes aggressively attack oral bacteria by reducing ... sanitizing technology. Combining leading edge Enke technology with a premium timeless design, they ...
(Date:9/22/2017)... ... September 22, 2017 , ... “Letters From Home”: a moving ... lost, have value to God. “Letters From Home” is the creation of published author, ... the President’s Cabinet of Jerry Savelle Ministries International, who has traveled and ministered on ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... and create life. Although frozen embryos have a slight statistical advantage for live ... freezing is a wonderful opportunity for women undergoing medical treatment or who are ...
(Date:9/21/2017)... ... 21, 2017 , ... With ProSlideshow Portrait from Pixel Film Studios creating a ... select from up to two layers of subject matter along with fully customizable backdrop ... Final Cut Pro X. , With ProSlideshow Portrait each user are given ...
(Date:9/21/2017)... ... 21, 2017 , ... Process Capability Indices for Medical Device ... ET, http://www.fdanews.com/processcapabilityindices      , Quality in device manufacturing is ... Quality System Regulation (§820.250), and Devicemakers find themselves staring at a warning letter. ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... ... ... – Monday, September 18 th .The Brain Tumor Foundation (BTF) begins ... the public.Where:  BTF,s Mobile MRI Unit – a ... Washington, D.C.What:BTF brings its nationwide initiative, the Road to Early Detection Sponsor-A-City ...
(Date:9/9/2017)... Lilly and Company (NYSE: LLY ) will ... an investigational, oral, first-in-class molecule for the acute treatment ... placebo in the Phase 3 SPARTAN study. Detailed results ... the International Headache Society (IHC) in Vancouver ... lasmiditan,s potential to reduce pain and provide freedom from ...
(Date:9/7/2017)... MIRAGE, Calif. , Sept. 7, 2017  For nearly two decades, ... service in the Assisted Reproduction Insurance industry. Today, New Life Agency announces ... fertility medications. ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ... ...
Breaking Medicine Technology: